Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 601-610 of 982 for hematology

Edit search filters
  1. Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia

    Scottsdale/Phoenix, AZ

  2. Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

    Scottsdale/Phoenix, AZ

  3. Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

    Scottsdale/Phoenix, AZ

  4. A Study to Evaluate Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently- Detectable Minimal Residual Disease

    Eau Claire, WI, Rochester, MN

  5. Allogeneic Transplant in HIV Patients (BMT CTN 0903)

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

    Rochester, MN

  7. Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

  8. LS138D, Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

    Rochester, MN

  9. A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    Jacksonville, FL

  10. Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer